1. Home
  2. CAC vs ESPR Comparison

CAC vs ESPR Comparison

Compare CAC & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Camden National Corporation

CAC

Camden National Corporation

N/A

Current Price

$50.51

Market Cap

857.1M

Sector

Finance

ML Signal

N/A

Logo Esperion Therapeutics Inc.

ESPR

Esperion Therapeutics Inc.

N/A

Current Price

$3.14

Market Cap

731.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CAC
ESPR
Founded
1875
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
857.1M
731.9M
IPO Year
1996
2013

Fundamental Metrics

Financial Performance
Metric
CAC
ESPR
Price
$50.51
$3.14
Analyst Decision
Buy
Strong Buy
Analyst Count
2
4
Target Price
$47.00
$8.75
AVG Volume (30 Days)
79.1K
9.8M
Earning Date
04-28-2026
05-07-2026
Dividend Yield
3.51%
N/A
EPS Growth
6.08
60.71
EPS
1.29
N/A
Revenue
$41,739,000.00
$403,135,000.00
Revenue This Year
$19.15
N/A
Revenue Next Year
$6.05
$12.81
P/E Ratio
$39.15
N/A
Revenue Growth
16.96
21.31
52 Week Low
$35.00
$0.95
52 Week High
$53.71
$4.18

Technical Indicators

Market Signals
Indicator
CAC
ESPR
Relative Strength Index (RSI) 58.08 69.96
Support Level $47.12 $3.11
Resistance Level $51.47 $3.18
Average True Range (ATR) 1.54 0.01
MACD 0.16 -0.03
Stochastic Oscillator 90.46 67.00

Price Performance

Historical Comparison
CAC
ESPR

About CAC Camden National Corporation

Camden National Corporation is a banking solutions provider in the United States. Its core business is providing commercial banking products to individuals and corporates. Its consumer and commercial banking services entail services such as loans and deposits, savings and online banking, treasury management solutions and non-profit products to consumer, institutional, municipal, non-profit and commercial customers. The company also offers investment management and fiduciary services.

About ESPR Esperion Therapeutics Inc.

Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.

Share on Social Networks: